Abstract
Persistent STAT5 activation endows antitumor CD4 + T cells with desirable functional features that optimize adoptive T cell therapy.
Funding Information
  • American Cancer Society (IRG14-193-01)
  • NIH Office of the Director (1R01CA215523)
  • NIH Office of the Director (1R03CA212829)
  • NIH Office of the Director (1R01CA238514)
  • National Institute of Allergy and Infectious Diseases (R37AI34495)

This publication has 92 references indexed in Scilit: